News

In January 2017, Acucela had received orphan drug designation from the US Food and Drug Administration (FDA) for emixustat to treat Stargardt disease. Stargardt disease is a rare

The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the

“Extending the life of transplanted kidneys would mean fewer patients going back on dialysis or needing a second transplant – relieving pressure on waiting lists that in the

Under the deal, Exonics equity holders will receive $245m (£192m) upfront payment from Vertex, as well as potential future payments based on the achievement of specified development and

The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetic profile of GFB-887 in healthy volunteers and in patients with chronic kidney disease. Topline safety data from

The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a

The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy of the combination in advanced

ADPKD is the most common inherited form of kidney disease affecting approximately 140,000 patients in the United States.  It is characterized by the development of pathologic fluid-filled cysts

Emgality, which is an advanced therapeutic approach for the neurologic disease, is claimed to be the first and only calcitonin gene-related peptide (CGRP) antibody approved by the FDA